ImmuPharma (LON:IMM) Announces Earnings Results

ImmuPharma (LON:IMM) issued its earnings results on Tuesday. The company reported GBX (0.84) EPS for the quarter, Digital Look Earnings reports. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%.

ImmuPharma Price Performance

LON:IMM opened at GBX 3.36 on Tuesday. The firm has a market capitalization of £20.96 million, a P/E ratio of -9.08 and a beta of 3.01. The business has a 50 day simple moving average of GBX 3.89 and a 200 day simple moving average of GBX 4.53. ImmuPharma has a 12-month low of GBX 3.02 and a 12-month high of GBX 18.90.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.